论文部分内容阅读
目的探讨左乙拉西坦联合家庭式干预治疗儿童癫痫的疗效及安全性分析。方法选择2013年1月—2016年3月收治的癫痫患儿80例,根据治疗方法的不同,分为观察组和对照组,每组40例,2组患儿年龄、病程、发作类型等差异无统计学意义。2组患儿均口服左乙拉西坦,治疗剂量为10 mg/kg,每日分为早晚2次服用,根据临床疗效及耐受性逐渐增加剂量至30 mg/(kg·d)。治疗医师应尽量使用最低的有效剂量控制癫痫发作,观察组在此基础上给予家庭式干预,2组患儿均治疗3个月。比较2组患儿的临床疗效、治疗后的认知功能及生活质量评分,观察并记录不良反应的发生情况。结果治疗后,观察组总有效率为87.50%,高于对照组的70.00%,差异有统计学意义(P<0.05)。观察组患儿治疗后各项生活质量评分均明显优于对照组患儿,差异均有统计学意义(P<0.05)。治疗后,观察组患儿智商、语言智商、操作智商、总智商评分均高于对照组患儿,差异均具有统计学意义(P<0.05)。2组患儿总不良反应发生率相当,差异无统计学意义(P>0.05)。结论左乙拉西坦联合家庭式干预,能显著提高患儿的临床疗效,提高患儿生活质量,提高患儿认知评分,且不良反应较少,因此安全性高,值得临床推广应用。
Objective To investigate the efficacy and safety of levetiracetam combined with family intervention in the treatment of children with epilepsy. Methods Eighty children with epilepsy admitted from January 2013 to March 2016 were divided into observation group and control group according to the different treatment methods. There were 40 cases in each group, and the difference of age, course of disease and type of attack between the two groups No statistical significance. Patients in both groups were treated with levetiracetam at a dose of 10 mg / kg daily for 2 times daily. The dosage was gradually increased to 30 mg / (kg • d) according to the clinical efficacy and tolerability. The treating physician should try to use the lowest effective dose to control seizures. The observation group was given family intervention on this basis. Both groups were treated for 3 months. The clinical efficacy, cognitive function and quality of life scores of two groups were compared, and the occurrence of adverse reactions was observed and recorded. Results After treatment, the total effective rate of the observation group was 87.50%, which was higher than that of the control group (70.00%), the difference was statistically significant (P <0.05). The quality of life scores of observation group children were significantly better than those of control group after treatment, the differences were statistically significant (P <0.05). After treatment, the scores of IQ, language IQ, operation IQ, and total IQ of observation group were higher than those of control group, the differences were statistically significant (P <0.05). The incidence of adverse reactions in both groups was similar, with no significant difference (P> 0.05). Conclusion Levetiracetam combined with family intervention can significantly improve the clinical efficacy of children, improve children’s quality of life, improve children’s cognitive score, and fewer adverse reactions, so it is safe and worthy of clinical application.